Document:

NTCT-EX10.8_2014.12.31

Exhibit 10.8

NetScout Systems, Inc.
Summary of Non-Employee Director Compensation
Effective as of November 2014, non-employee directors are compensated $36,000 annually for their services and do not receive any additional compensation for any regular Board meeting attended. The lead non-employee director receives an additional annual retainer of $30,000. Non-employee directors currently receive $10,000 annually for serving on the Audit Committee, $8,000 annually for serving on the Compensation Committee, and $6,000 annually for serving on the Nominating Committee. In addition, directors who are chairpersons of a particular committee are also given additional annual compensation of $20,000 for the Audit Committee, and $10,000 for the Compensation Committee, and $8,000 for the Nominating Committee and $6,000 for the Finance Committee. Finance Committee members receive $1,000 for each meeting attended in person and $800 for each meeting attended via telephone. Non-employee directors are also reimbursed for their reasonable out-of-pocket expenses incurred in attending meetings of the Board or of any committee and for attendance at approved director education programs.
Non-employee directors are granted annually equity-based awards in the form of restricted stock units and related cash amounts upon vesting to defray the corresponding tax liability as follows:
 
	
													
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Element
	 
	Role/Position
	 

	 
	Lead Director
	 
	 
	Chairperson
	 
	 
	Other Directors
	 

	Total value (RSU Grant and Cash Offset)
	 
	$
	212,000
	 
	 
	$
	159,000
	 
	 
	$
	132,500
	 

	RSU Grant
	 
	$
	132,000
	 
	 
	$
	99,000
	 
	 
	$
	82,500
	 

	Cash Offset
	 
	$
	80,000
	 
	 
	$
	60,000
	 
	 
	$
	50,000
	 

These restricted stock unit awards vest 100% on the date of our annual meeting provided that during such year, such director attends at least 75%, collectively, of the meetings of the Board and any committee of the Board of which such director is a member. In the event that the foregoing attendance requirements are not met, then 100% of these restricted stock units will vest on the third anniversary of the date of grant. No other equity awards are given to our non-employee directors.NTCT-EX10.9_2014.12.31

Exhibit 10.9

FORM OF AMENDMENT TO AMENDED AND RESTATED SEVERANCE AGREEMENT 
FOR EXECUTIVE OFFICERS 

THIS AMENDMENT TO AMENDED AND RESTATED SEVERANCE AGREEMENT, dated effective as of [_____] (the “Amendment”), is made by and between NetScout Systems, Inc. (the “Company”), and [Name] (the “Executive”) residing at [Address].

WHEREAS, the Company and the Executive are party to an Amended and Restated Severance Agreement (the “Severance Agreement”); and 

WHEREAS, the Company and the Executive desire to clarify that the effectuation of the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of October 12, 2014, as may be amended from time to time, by and between the Company, Danaher Corporation, Potomac Holding LLC, RS Merger Sub I, Inc., and RS Merger Sub II, LLC (the “Merger Agreement”) do not constitute a Change in Control for purposes of the Severance Agreement;

THEREFORE, in consideration of the foregoing and other respective covenants and agreements of the parties herein contained, the parties hereto agree that the Severance Agreement is hereby amended as follows: 

1.Defined Terms. The definition of “Change in Control” set forth in the Severance Agreement is hereby amended to add the additional following paragraph at the end of such defintion:

“Notwithstanding anything in the foregoing to the contrary, no Change in Control shall be deemed to have occurred for purposes of this Agreement as a result of the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of October 12, 2014, as may be amended from time to time, by and between the Company, Danaher Corporation, Potomac Holding LLC, RS Merger Sub I, Inc., and RS Merger Sub II, LLC.”

2.   Assignment.  This Amendment and the Severance Agreement and the rights and obligations of the parties hereto shall bind and inure to the benefit of any successor of the Company by reorganization, merger or consolidation and any assignee of all or substantially all of its business and properties.  Neither the Severance Agreement, as amended by this Amendment, nor any rights or benefits hereunder or thereunder may be assigned by the Executive, except that, upon the Executive’s death, the Executive’s earned and unpaid economic benefits will be paid to the Executive’s heirs or beneficiaries.

3.   Governing Law; Arbitration.  The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the Commonwealth of Massachusetts, without regard to its conflict of laws provisions.  Any dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by arbitration in Boston, Massachusetts in accordance with the rules of the American Arbitration Association then in effect.  Judgment may be entered on the arbitrator’s award in any court having jurisdiction.  
4.  Miscellaneous.  No provision of this Amendment may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by the Executive and the Chief Executive Officer of the Company.  No waiver by either party hereto at any time of any breach by the other party hereto of, or of any lack of compliance with, any condition or provision of this Amendment to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. This Amendment supersedes and is in lieu of any other agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof (including any severance agreement by and between the Company and the Executive) which have been made by either party.  The invalidity or unenforceability of any provision of this Amendment shall not affect the validity or enforceability of any other provision of this Amendment, which shall remain in full force and effect.
5.  Counterparts. This Amendment may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.

    
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Company and the Executive have signed this Agreement as of the date first above written.  

NETSCOUT SYSTEMS, INC.

By: ______________________
Name:
Title:

EXECUTIVE:

____________________________
[Signature]

____________________________
[Print Name]EXHIBIT 10.1

  

	NHS
    PHARMA, Inc.

 

SCRIPT
PROCESSING SERVICE CONTRACT

 

	1.	This
    contract is entered into and between NHS PHARMA, INC., a California corporation whose address is 1323 W Colton Ave., Suite
    120, Redlands, CA 92374 referred to as “NHS, and Mesa Pharmacy, Inc., a California Corporation, herein after referred to as
    “NEW PHARMACY” whose address is:
	 	 
	2.	NEW
    PHARMACY desires to process scripts to be able to receive payments from insurance companies, NHS provides insurance processing
    services by electronic and Software means for scripts and agrees to provide such services to NEW PHARMACY on the terms and
    conditions set forth in this contract and agreed to by the parties as follows:
	 	 
	3.	For
    purposes of this contract, a claim is defined as the submission of information being sent to insurance companies for medication
    being recommended by a physician to be filled by a Pharmacist for their patient.
	 	 
	4.	NHS
    will provide the script submissions to insurance carriers on behalf of NEW PHARMACY.
	 	 
	5.	NEW
    PHARMACY agrees to adhere to NHS’s procedures and instructions for the processing of scripts. NEW PHARMACY will provide
    NHS a script from a licensed medical provider in order for NHS to perform its duties.
	 	 
	6.	On
    receipt of the scripts, NHS will provide the billing services requested and provide the reports to NEW PHARMACY according
    to each script transmission. Every attempt will be made to stop incomplete or incorrect information in order to get an approved
    and paid script.
	 	 
	7.	The
    initial contract period will be in effect for 3 years.
	 	 
	COMPENSATION:
	 	 
	8.	NEW
    PHARMACY agrees to compensate NHS for it’s services rendered in accordance with the prices set forth in the attached
    Addendum A and incorporated into this contract and made a part hereof.
	 	 
	9.	An
    invoice will be either faxed or e-mailed to NEW PHARMACY for payment. More information is attached in the Addendum A.
	 	 
	10.	Any
    software, hardware, or materials provided by NHS at no cost to NEW PHARMACY, remains the property of NHS and is for NEW PHARMACY’S
    use only during the period NEW PHARMACY maintains a current NHS service contract. NEW PHARMACY agrees to return all NHS’s
    property and any copies thereof upon demand or termination of this agreement by either party.
	 	 
	CONFIDENTIALY:
	 	 
	11.	All
    statistical, financial, and personal data relating to NEW PHARMACY business which are confidential and clearly designated
    as such, will be kept in the strictest confidence by NHS and it’s employees.

 

    	1 | Page

    	 

    

 

	NHS
    PHARMA, Inc.

 

	12.	All
    programs, instruction procedures, specifications, applications, routines, subroutines, techniques, ideas, and formulae utilized
    by NHS in connection with this agreement, arc, and shall remain, the sole property of the NHS unless otherwise provided for
    in this agreement.
	 	 
	NHS’S
    RESPONSIBILITIES:
	 	 
	13.	NHS
    is a HIPAA Compliant Company and will use care in processing NEW PHARMACY claims, but it will be responsible only to the extent
    of correction of any error due to NHS’s operators, and/or programmers provided NEW PHARMACY has notified the NHS in
    writing of any claimed error identified within six months from any claim transaction’s date of service. Such corrections
    will be at no additional charge to NEW PHARMACY. NHS shall not be liable for failure to provide, or delays in providing, services
    hereunder, if due to any cause beyond NHS’s reasonable control. NHS will assist NEW PHARMACY in any audit proceedings,
    by way of proof of documentation of all billing records, either from billed out claims and Payer reporting from billing processed
    by NHS.
	 	 
	14.	This
    item has been left intentionally blank.
	 	 
	15.	NHS
    is not liable for the claim amounts owed or policies set by insurance carriers or any other type payers in determining claim
    payments, nor for their actions or decisions.
	 	 
	16.	This
    Script Processing Service Contract in addition to the Business Associate agreement represent the entire agreement between
    the parties, with respect to the subject matter hereunder. Except as herein expressly provided otherwise, the provisions of
    this agreement are for the sole benefit of the parties and not for the benefit of any other person, persons or legal entities.
	 	 
	17.	No
    agreement, guaranty, promise, representation, waiver, alteration, modification, or warranty of any of the provisions of this
    agreement shall be binding unless acknowledged in writing and signed by a duly authorized agent for NHS.
	 	 
	18.	All
    communications to NHS regarding this agreement shall be sent to the following address unless NHS notifies NEW PHARMACY in
    writing of a change of address: NHS Pharma, P.O. Box 455 Redlands, CA, 92373.
	 	 
	ATTORNEY’S
    FEES AND COSTS:
	 	 
	19.	If
    any action at law or in equity is necessary to enforce or interpret the terms of this agreement, the prevailing party shall
    be entitled to reasonable attorney fees, and necessary disbursements in addition to any other relief to which such party may
    be entitled.
	 	 
	20.	This
    agreement shall not be binding until signed by the authorized agent by both parties. It shall continue in full force and effect
    until it is terminated.

 

    	2 | Page

    	 

    

 

	NHS
    PHARMA, Inc.

 

	GOVERNING
    LAW, ENTIRETY OF AGREEMENT, AND PARTIAL INVALIDITY
	 	 
	21.	This
    agreement shall be governed by the laws of the State of California. If any provision of this contract is held by any court
    to be invalid, void, or unenforceable, the remaining provisions shall nonetheless continue in full force and effect.

 

Executed
   Dec 4   2014 at Redlands, California.

 

	 	 
	Signature
    of NHS PHARMA, Inc. Representative	 
	 	 
	Ron
    Green	 
	NHS
    PHARMA, Inc., Representative	 
		 
	Signature
    of NEW PHARMACY, Inc., Representative	 
	 	 
	NEW
    PHARAMCY COMPOUNDING PHARMACY, Inc., Representative

  

    	3 | Page

    	 

    

 

	NHS
    PHARMA, Inc.

 

Addendum
A-Compensation and Services

 

The
parties agree that the compensation that will be paid to NHS PHARMA, INC will be based on the following:

 

Once
a script has been billed and NHS PHARMA, Inc. has received an approval from the insurance payer, the insurance payer will commit
to pay the Pharmacy a specific amount. That committed amount is the amount that will be used to calculate the payments to NHS
and will be invoiced to the Pharmacy. Invoices will be sent to the Pharmacy by-monthly. All committed amounts from the 1st of
the month to the 15th will be invoiced to the pharmacy for payment to NHS the 1st of the following month.
All committed amounts from the 16th of the month to the 30th will be invoiced for payment on the 15th
day of the following month.

 

	Billing
    Services	7
    1⁄2%
	Script
    Collection	Script
    Processing (PK Software)
	Eligibility
    and Payment Check	Data
    Base entry (PK Software)
	Calling
    Payers on Pre-Auths	Reporting
    (Pharmacy, Doctor and Rep)
	Patient
    and Doctor contacting	Financial
    Tracking
	 	 
	Additional
    Services offered	1
    1⁄2%
	Patient
    Refill calls	 
	Patient
    Denial calls	 
	Patient
    Compliance calls	 
	Medication
    Usage	 
	Updating
    Insurance Information	 
	Updating
    Correct ship- to info	 
	Verifying
    someone will be there to sign	 
	Collection
    of Co-pays	 
	Real
    Time, Online Portal Reporting	 
	Script Tracking on Approvals, Denials, In-Processing and problems
	Financial
    Tracking	 

 

    	4 | Page

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]